— Know what they know.
Not Investment Advice
Also trades as: SMSPHARMA.BO (BSE) · $vol 0M

SMSPHARMA.NS NSE

SMS Pharmaceuticals Limited
1W: -0.6% 1M: +28.0% 3M: +11.8% YTD: +48.0% 1Y: +101.9% 3Y: +294.5% 5Y: +166.9%
₹470.95 ($4.90)
-5.65 (-1.19%)
 
NSE · Healthcare · Drug Manufacturers - General · Tech Score Strong Buy · Power 74 · ₹44.1B mcap · 5M float · 13.05% daily turnover

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C
Oct 01, 2026
DCF
1
ROE
4
ROA
1
D/E
1
P/E
1
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. SMSPHARMA.NS receives an overall rating of C. Strongest factors: ROE (4/5). Areas of concern: DCF (1/5), ROA (1/5), D/E (1/5), P/E (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-08-19 D+ C
2026-08-03 B- D+
2026-05-25 D+ B-
2026-02-10 B- D+
2026-01-03 B B-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 54 Grade B
Profitability
43
Balance Sheet
65
Earnings Quality
61
Growth
67
Value
44
Momentum
79
Safety
100
Cash Flow
24
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. SMSPHARMA.NS scores highest in Safety (100/100) and lowest in Cash Flow (24/100). A grade of B indicates above-average fundamentals with room for improvement in select areas.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
5.28
Safe Zone
Piotroski F-Score
7/9
✓ ✓ ✓ ✗ ✓ ✓ ✗ ✓ ✓
Beneish M-Score
-2.12
Unlikely Manipulator
Ohlson O-Score
-9.07
Bankruptcy prob: 0.0%
Low Risk
Credit Rating
A-
Score: 69.8/100
Trend: Improving
Earnings Quality
75/100
OCF/NI: 0.82x
Accruals: 1.4%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. SMSPHARMA.NS scores 5.28, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. SMSPHARMA.NS scores 7/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. SMSPHARMA.NS's score of -2.12 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. SMSPHARMA.NS's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. SMSPHARMA.NS receives an estimated rating of A- (score: 69.8/100), with a improving trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). SMSPHARMA.NS's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
41.90x
PEG
1.31x
P/S
4.90x
P/B
5.62x
P/FCF
-85.78x
P/OCF
40.75x
EV/EBITDA
21.15x
EV/Revenue
4.22x
EV/EBIT
27.30x
EV/FCF
-93.77x
Earnings Yield
2.98%
FCF Yield
-1.17%
Shareholder Yield
0.18%
Graham Number
$146.95
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 41.9x earnings, SMSPHARMA.NS is priced for high growth expectations. Graham's intrinsic value formula yields $146.95 per share, 220% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.781
NI / EBT
×
Interest Burden
0.953
EBT / EBIT
×
EBIT Margin
0.155
EBIT / Rev
×
Asset Turnover
0.705
Rev / Assets
×
Equity Multiplier
1.764
Assets / Equity
=
ROE
14.3%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. SMSPHARMA.NS's ROE of 14.3% is driven by Asset Turnover (0.705), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
15.00%
Fair P/E
38.50x
Intrinsic Value
$429.70
Price/Value
0.87x
Margin of Safety
12.76%
Premium
-12.76%
Assessment
Neutral
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with SMSPHARMA.NS's realized 15.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. SMSPHARMA.NS trades at a -13% premium to its adjusted intrinsic value of $429.70, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 38.5x compares to the current market P/E of 41.9x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$471.30
Median 1Y
$564.81
5th Pctile
$264.85
95th Pctile
$1212.15
Ann. Volatility
47.4%
25th–75th percentile 5th–95th percentile Median path Historical
All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
ROE 20.8% 22.2% 19.2% 14.1% 5.8% 0.1% -1.0% -1.6% 3.1% 6.1% 7.7% 10.0% 11.4% 11.4% 12.7% 11.8% 12.4% 13.0% 13.9% 14.3% 14.31%
ROA 11.1% 11.6% 10.0% 7.4% 3.1% 0.1% -0.5% -0.9% 1.7% 3.1% 3.9% 5.2% 6.0% 5.6% 6.3% 6.3% 6.7% 7.0% 7.4% 8.1% 8.11%
ROIC 13.0% 14.3% 13.1% 11.8% 8.1% 0.5% -0.3% 2.6% 5.6% 7.2% 8.0% 8.4% 9.1% 8.5% 9.0% 8.5% 8.9% 9.8% 10.4% 9.3% 9.28%
ROCE 20.0% 22.3% 21.0% 13.1% 6.2% 1.2% -0.2% 4.1% 8.5% 10.6% 12.2% 12.6% 13.7% 13.1% 13.7% 13.4% 13.8% 14.4% 15.6% 13.6% 13.59%
Gross Margin 38.7% 36.4% 38.1% 14.9% 24.2% 19.0% 24.8% 30.6% 35.1% 30.1% 31.4% 14.3% 20.1% 30.0% 38.7% 16.0% 33.3% 31.7% 20.8% 17.5% 17.52%
Operating Margin 22.4% 22.2% 15.6% -21.7% -13.6% 3.8% 8.5% 10.8% 14.0% 12.4% 13.0% 11.0% 15.3% 11.6% 14.1% 13.0% 15.1% 15.8% 16.0% 12.5% 12.51%
Net Margin 14.5% 13.2% 7.4% 11.4% -19.8% -1.3% 2.5% 2.3% 6.9% 7.0% 7.1% 7.0% 10.0% 7.2% 10.5% 8.2% 10.5% 10.4% 11.2% 13.7% 13.75%
EBITDA Margin 28.1% 27.6% 24.1% -7.2% -0.0% 8.9% 13.9% 16.4% 19.7% 17.2% 18.9% 14.3% 21.2% 16.7% 20.4% 17.0% 20.4% 20.5% 22.5% 16.8% 16.77%
FCF Margin -5.3% -7.1% -9.8% -8.3% -5.8% 1.8% 9.1% 9.9% 10.8% 10.6% 10.3% 6.6% 4.2% 1.9% -0.3% -2.1% -3.7% -2.0% -3.5% -4.5% -4.50%
OCF Margin 10.7% 11.9% 14.4% 15.1% 15.7% 14.7% 12.3% 11.2% 10.8% 10.6% 10.3% 8.4% 7.7% 7.0% 6.4% 6.9% 7.0% 10.1% 10.1% 9.5% 9.48%
ROE 3Y Avg snapshot only 11.03%
ROE 5Y Avg snapshot only 8.92%
ROA 3Y Avg snapshot only 6.10%
ROIC 3Y Avg snapshot only 6.83%
ROIC Economic snapshot only 9.05%
Cash ROA snapshot only 6.17%
Cash ROIC snapshot only 7.61%
CROIC snapshot only -3.61%
NOPAT Margin snapshot only 11.56%
Pretax Margin snapshot only 14.73%
R&D / Revenue snapshot only 0.00%
SGA / Revenue snapshot only 4.41%
SBC / Revenue snapshot only 0.00%
Valuation
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
P/E Ratio 18.37 14.30 13.57 12.65 26.65 1231.60 -151.55 -65.42 52.50 37.50 27.80 30.21 33.06 49.84 30.62 26.08 30.36 25.95 31.40 33.59 41.899
P/S Ratio 2.38 1.99 1.70 1.52 1.64 1.83 1.63 0.94 1.29 1.77 1.64 2.12 2.55 3.85 2.59 2.30 2.73 2.55 3.14 3.86 4.903
P/B Ratio 3.54 2.87 2.35 1.67 1.45 1.62 1.54 1.07 1.67 2.22 2.09 2.81 3.51 5.25 3.59 2.82 3.47 3.00 3.86 4.36 5.619
P/FCF -45.16 -27.89 -17.42 -18.35 -28.28 99.87 17.92 9.50 12.03 16.77 15.87 32.24 61.14 204.11 -994.31 -111.01 -72.94 -126.72 -89.35 -85.78 -85.780
P/OCF 22.31 16.76 11.80 10.06 10.45 12.47 13.27 8.40 12.03 16.77 15.87 25.20 33.11 55.17 40.37 33.56 38.74 25.13 31.01 40.75 40.747
EV/EBITDA 11.26 8.86 7.76 8.41 12.27 25.11 30.78 12.42 11.77 12.94 11.25 14.45 16.46 24.15 16.55 14.27 16.57 14.41 16.92 21.15 21.148
EV/Revenue 2.73 2.32 2.04 1.94 2.16 2.46 2.22 1.41 1.71 2.17 2.02 2.47 2.88 4.19 2.93 2.65 3.06 2.80 3.38 4.22 4.222
EV/EBIT 13.52 10.53 9.46 11.52 21.83 136.56 -763.31 28.47 19.18 19.27 16.03 19.72 22.11 32.34 22.04 18.69 21.73 18.52 21.53 27.30 27.303
EV/FCF -51.82 -32.52 -20.95 -23.42 -37.25 134.29 24.42 14.28 15.90 20.52 19.64 37.48 69.09 222.36 -1124.25 -127.58 -81.78 -139.58 -96.40 -93.77 -93.768
Earnings Yield 5.4% 7.0% 7.4% 7.9% 3.8% 0.1% -0.7% -1.5% 1.9% 2.7% 3.6% 3.3% 3.0% 2.0% 3.3% 3.8% 3.3% 3.9% 3.2% 3.0% 2.98%
FCF Yield -2.2% -3.6% -5.7% -5.5% -3.5% 1.0% 5.6% 10.5% 8.3% 6.0% 6.3% 3.1% 1.6% 0.5% -0.1% -0.9% -1.4% -0.8% -1.1% -1.2% -1.17%
PEG Ratio snapshot only 1.312
Price/Tangible Book snapshot only 4.375
EV/OCF snapshot only 44.541
EV/Gross Profit snapshot only 16.443
Acquirers Multiple snapshot only 28.505
Shareholder Yield snapshot only 0.18%
Graham Number snapshot only $146.95
Leverage & Solvency
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Current Ratio 1.58 1.64 1.64 1.92 1.92 1.66 1.66 1.61 1.61 1.47 1.47 1.61 1.61 1.55 1.55 1.71 1.71 1.76 1.76 1.81 1.808
Quick Ratio 0.88 0.69 0.69 0.64 0.64 0.54 0.54 0.73 0.73 0.65 0.65 0.90 0.90 0.71 0.71 0.83 0.83 0.92 0.92 0.81 0.813
Debt/Equity 0.62 0.54 0.54 0.56 0.56 0.56 0.56 0.55 0.55 0.58 0.58 0.52 0.52 0.51 0.51 0.49 0.49 0.44 0.44 0.46 0.465
Net Debt/Equity 0.52 0.48 0.48 0.46 0.46 0.56 0.56 0.54 0.54 0.50 0.50 0.46 0.46 0.47 0.47 0.42 0.42 0.30 0.30 0.41 0.406
Debt/Assets 0.31 0.28 0.28 0.31 0.31 0.30 0.30 0.29 0.29 0.28 0.28 0.27 0.27 0.25 0.25 0.27 0.27 0.25 0.25 0.27 0.268
Debt/EBITDA 1.72 1.44 1.49 2.21 3.59 6.45 8.22 4.28 2.95 2.75 2.51 2.32 2.17 2.14 2.06 2.14 2.07 1.94 1.81 2.06 2.062
Net Debt/EBITDA 1.45 1.26 1.31 1.82 2.96 6.44 8.20 4.15 2.87 2.37 2.16 2.02 1.89 1.98 1.91 1.85 1.79 1.33 1.24 1.80 1.802
Interest Coverage 10.05 10.05 8.39 4.79 2.28 0.39 -0.06 1.28 2.44 3.07 3.51 3.78 4.41 4.78 5.44 5.98 5.81 6.25 6.17 5.94 5.943
Equity Multiplier 1.98 1.94 1.94 1.83 1.83 1.89 1.89 1.91 1.91 2.04 2.04 1.93 1.93 2.01 2.01 1.80 1.80 1.75 1.75 1.73 1.734
Cash Ratio snapshot only 0.131
Debt Service Coverage snapshot only 7.673
Cash to Debt snapshot only 0.126
FCF to Debt snapshot only -0.109
Defensive Interval snapshot only 992.2 days
Efficiency & Turnover
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Asset Turnover 0.86 0.84 0.80 0.62 0.50 0.46 0.49 0.60 0.68 0.65 0.67 0.74 0.77 0.73 0.74 0.72 0.74 0.71 0.74 0.71 0.705
Inventory Turnover 2.99 2.28 2.15 1.72 1.45 1.24 1.39 1.66 1.82 1.56 1.55 2.30 2.49 1.99 1.98 2.25 2.25 1.93 2.12 2.07 2.073
Receivables Turnover 7.91 7.18 6.88 6.68 5.40 3.90 4.16 5.30 6.02 4.84 4.94 3.69 3.84 4.18 4.24 3.56 3.71 3.96 4.13 4.23 4.232
Payables Turnover 11.16 4.42 4.16 6.97 5.90 3.00 3.36 4.93 5.42 3.25 3.24 4.88 5.28 3.15 3.13 5.13 5.12 3.44 3.78 5.63 5.625
DSO 46 51 53 55 68 94 88 69 61 75 74 99 95 87 86 102 98 92 88 86 86.2 days
DIO 122 160 170 213 251 294 262 220 200 234 235 159 147 183 185 162 162 189 172 176 176.1 days
DPO 33 83 88 52 62 122 108 74 67 112 113 75 69 116 117 71 71 106 96 65 64.9 days
Cash Conversion Cycle 135 129 136 215 257 266 241 215 193 197 196 183 172 155 154 193 189 175 164 197 197.4 days
Fixed Asset Turnover snapshot only 1.358
Operating Cycle snapshot only 262.3 days
Cash Velocity snapshot only 19.249
Capital Intensity snapshot only 1.536
Growth (YoY)
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue 51.6% 57.8% 29.8% -8.2% -31.8% -38.8% -31.7% 1.4% 42.4% 49.6% 43.0% 35.9% 24.5% 28.0% 27.3% 10.4% 10.3% 11.9% 15.0% 13.3% 13.30%
Net Income 1.6% 1.8% 71.9% -0.9% -67.6% -99.3% -1.1% -1.1% -43.0% 46.5% 8.8% 7.6% 2.9% 1.1% 83.3% 38.8% 28.4% 42.2% 35.5% 47.5% 47.52%
EPS 1.6% 1.8% 73.5% -0.9% -67.5% -99.3% -1.1% -1.1% -43.1% 46.0% 8.8% 7.6% 2.9% 1.1% 82.9% 38.4% 22.3% 34.7% 26.9% 37.0% 36.97%
FCF -23.0% -14.5% -19.3% -1.4% 24.9% 1.2% 1.6% 2.2% 3.6% 7.6% 62.2% -9.6% -51.7% -77.1% -1.0% -1.3% -2.0% -2.2% -14.5% -1.5% -1.46%
EBITDA 79.8% 1.0% 67.7% -4.4% -50.5% -77.1% -81.3% -50.1% 17.5% 1.6% 2.6% 1.0% 50.1% 32.7% 25.3% 19.9% 16.3% 25.4% 29.8% 21.9% 21.93%
Op. Income 1.1% 1.4% 81.6% -16.8% -69.1% -97.1% -1.0% -68.2% 46.4% 15.7% 35.3% 2.4% 74.4% 40.1% 29.4% 19.4% 16.4% 30.0% 34.5% 25.5% 25.52%
OCF Growth snapshot only 56.47%
Asset Growth snapshot only 18.20%
Equity Growth snapshot only 22.85%
Debt Growth snapshot only 17.47%
Shares Change snapshot only 7.70%
Dividend Growth snapshot only 1.07%
Growth (CAGR)
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue 3Y 0.7% 4.4% 7.4% 3.7% -2.8% -2.8% 1.0% 8.6% 13.7% 13.1% 8.2% 8.1% 6.5% 5.4% 7.5% 15.0% 25.1% 28.9% 27.9% 19.3% 19.32%
Revenue 5Y 1.3% 2.3% 1.6% -1.8% -6.5% -7.4% -6.6% -3.5% -0.1% 0.8% 3.9% 9.0% 10.2% 12.0% 13.4% 14.0% 15.1% 15.7% 13.1% 9.6% 9.60%
EPS 3Y 25.8% 33.1% 30.6% 15.6% -14.3% -75.4% — — -22.1% -4.1% -7.7% -7.3% -10.3% -13.2% -6.0% 3.6% 39.6% 4.1% — — —
EPS 5Y 19.3% 20.5% 17.6% 12.6% -8.3% -56.6% — — -18.1% -6.0% 0.2% 4.4% 7.0% 8.0% 11.3% 16.8% 17.7% 20.1% 12.8% 8.6% 8.58%
Net Income 3Y 26.0% 33.2% 30.0% 15.7% -14.2% -75.5% — — -22.1% -4.0% -7.7% -7.3% -10.4% -13.3% -5.6% 3.7% 41.8% 4.2% — — —
Net Income 5Y 19.3% 20.5% 17.4% 12.6% -8.3% -56.7% — — -18.1% -6.0% 0.1% 4.5% 7.0% 8.0% 11.3% 16.9% 18.8% 21.4% 14.4% 10.3% 10.28%
EBITDA 3Y 13.9% 19.5% 17.6% 8.5% -7.7% -23.9% -28.3% -11.0% 1.5% 6.1% 3.8% -0.9% -4.4% -8.1% -5.8% 6.9% 27.0% 62.0% 79.8% 43.9% 43.92%
EBITDA 5Y 14.1% 13.5% 10.0% 3.0% -7.6% -17.2% -19.8% -9.7% -3.0% 0.0% 1.7% 5.4% 6.7% 8.4% 10.6% 11.5% 12.8% 14.7% 12.7% 7.3% 7.29%
Gross Profit 3Y 1.1% 8.3% 12.7% 10.5% -0.5% -8.8% -10.8% 0.3% 8.8% 12.5% 10.6% 0.4% -7.2% -9.3% -6.1% 3.1% 20.0% 35.3% 35.3% 21.0% 21.02%
Gross Profit 5Y 3.1% 4.4% 3.9% -1.8% -8.4% -13.7% -15.7% -10.5% -4.8% -0.8% 3.4% 6.4% 4.5% 6.1% 8.7% 9.3% 13.2% 14.5% 9.5% 4.7% 4.65%
Op. Income 3Y 15.7% 22.7% 18.2% 4.9% -19.4% -60.4% — -23.5% -1.3% 6.1% 2.5% -3.8% -7.6% -11.8% -8.5% 8.5% 43.8% 2.1% — 71.5% 71.54%
Op. Income 5Y 14.3% 13.6% 13.4% 3.6% -13.2% -42.6% — -19.3% -6.9% -2.0% -0.4% 4.3% 6.0% 7.6% 10.5% 12.5% 14.3% 16.9% 13.4% 5.9% 5.94%
FCF 3Y — — — — — -21.0% 55.1% 1.1% 2.5% — — — — — — — — — — — —
FCF 5Y — — — — — -13.9% 1.0% — — — 49.5% 19.6% 12.6% -0.6% — — — — — — —
OCF 3Y 6.5% 18.7% 27.5% 24.1% 13.0% 5.8% 3.6% 9.3% 14.7% 16.9% 16.7% 4.5% -4.4% -11.7% -17.9% -11.6% -4.3% 13.9% 20.0% 12.9% 12.88%
OCF 5Y -0.0% 2.6% 4.7% 0.6% -3.7% -4.6% -5.6% -2.3% 3.4% 6.4% 7.7% 7.9% 4.7% 1.5% 1.2% 3.7% 6.3% 17.0% 18.0% 9.9% 9.92%
Assets 3Y 17.4% 20.5% 20.5% 15.4% 15.4% 14.6% 14.6% 13.1% 13.1% 12.3% 12.3% 8.4% 8.4% 8.9% 8.9% 10.3% 10.3% 14.2% 14.2% 15.7% 15.70%
Assets 5Y 9.9% 11.7% 10.2% 9.7% 7.8% 7.7% 5.5% 6.1% 11.8% 14.2% 14.2% 13.1% 13.1% 14.8% 14.8% 13.7% 13.7% 13.1% 13.1% 10.9% 10.90%
Equity 3Y 13.0% 16.9% 16.9% 13.5% 13.5% 10.4% 10.4% 9.8% 9.8% 9.4% 9.4% 9.3% 9.3% 7.4% 7.4% 10.8% 10.8% 17.2% 17.2% 19.5% 19.50%
Book Value 3Y 12.8% 16.8% 17.4% 13.4% 13.4% 10.7% 10.4% 9.6% 9.8% 9.2% 9.3% 9.3% 9.4% 7.5% 7.0% 10.7% 9.0% 14.8% 14.6% 16.5% 16.49%
Dividend 3Y -17.2% -37.0% — -45.1% -20.8% 0.2% — -0.1% — — — -0.0% — — — 62.8% 30.5% 42.5% 30.8% 27.3% 27.29%
Growth Quality
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue Stability 0.05 0.01 0.00 0.02 0.13 0.08 0.09 0.10 0.01 0.00 0.08 0.58 0.44 0.40 0.55 0.90 0.88 0.84 0.77 0.80 0.796
Earnings Stability 0.39 0.38 0.58 0.56 0.01 0.01 0.03 0.10 0.09 0.04 0.04 0.02 0.00 0.00 0.00 0.02 0.07 0.09 0.12 0.17 0.169
Margin Stability 0.93 0.92 0.91 0.92 0.92 0.85 0.80 0.86 0.90 0.87 0.81 0.85 0.84 0.82 0.78 0.84 0.87 0.88 0.84 0.88 0.882
Rev. Growth Consistency 0.50 0.50 1.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earn. Growth Consistency 0.50 0.50 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0
Earnings Persistence 0.50 0.50 0.50 1.00 0.50 0.50 0.20 0.20 0.83 0.50 0.20 0.20 0.50 0.50 0.50 0.50 0.89 0.83 0.86 0.81 0.810
Earnings Smoothness 0.12 0.04 0.47 0.99 0.00 0.00 — — 0.45 0.00 — — 0.00 0.29 0.41 0.68 0.75 0.65 0.70 0.62 0.616
ROE Trend 0.09 0.10 0.05 0.01 -0.09 -0.14 -0.16 -0.16 -0.09 -0.04 -0.01 0.04 0.06 0.08 0.08 0.07 0.05 0.03 0.03 0.03 0.029
Gross Margin Trend 0.04 0.06 0.07 0.03 -0.01 -0.08 -0.12 -0.09 -0.06 -0.01 0.02 -0.04 -0.07 -0.04 -0.02 0.00 0.03 0.02 -0.03 0.00 0.000
FCF Margin Trend -0.07 -0.08 -0.11 -0.07 -0.03 0.06 0.14 0.16 0.16 0.13 0.11 0.06 0.02 -0.04 -0.10 -0.10 -0.11 -0.08 -0.09 -0.07 -0.068
Sustainable Growth Rate 20.2% 21.9% 19.2% 13.9% 5.5% -0.1% — — 3.1% 6.1% 7.7% 9.9% 11.2% 11.0% 12.2% 11.3% 11.9% 12.1% 12.9% 13.5% 13.45%
Internal Growth Rate 12.1% 12.9% 11.1% 7.9% 3.0% — — — 1.7% 3.2% 4.1% 5.4% 6.2% 5.8% 6.4% 6.5% 6.9% 7.0% 7.4% 8.3% 8.25%
Cash Flow Quality
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
OCF/Net Income 0.82 0.85 1.15 1.26 2.55 98.80 -11.42 -7.79 4.37 2.24 1.75 1.20 1.00 0.90 0.76 0.78 0.78 1.03 1.01 0.82 0.824
FCF/OCF -0.49 -0.60 -0.68 -0.55 -0.37 0.12 0.74 0.88 1.00 1.00 1.00 0.78 0.54 0.27 -0.04 -0.30 -0.53 -0.20 -0.35 -0.48 -0.475
FCF/Net Income snapshot only -0.392
OCF/EBITDA snapshot only 0.475
CapEx/Revenue 15.9% 19.0% 24.2% 23.4% 21.5% 12.9% 3.2% 1.3% 0.0% 0.0% 0.0% 1.8% 3.5% 5.1% 6.7% 8.9% 10.8% 12.1% 13.6% 14.0% 13.98%
CapEx/Depreciation snapshot only 3.106
Accruals Ratio 0.02 0.02 -0.01 -0.02 -0.05 -0.07 -0.07 -0.08 -0.06 -0.04 -0.03 -0.01 0.00 0.01 0.02 0.01 0.01 -0.00 -0.00 0.01 0.014
Sloan Accruals snapshot only 0.012
Cash Flow Adequacy snapshot only 0.646
Earnings Quality Score snapshot only 0.750
Dividends & Buybacks
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Dividend Yield 0.2% 0.1% 0.0% 0.1% 0.2% 0.2% 0.2% 0.1% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.1% 0.2% 0.1% 0.3% 0.2% 0.2% 0.08%
Dividend/Share $0.30 $0.15 $0.00 $0.08 $0.15 $0.15 $0.15 $0.07 $0.00 $0.00 $0.00 $0.08 $0.15 $0.23 $0.30 $0.32 $0.33 $0.66 $0.67 $0.67 $0.40
Payout Ratio 3.2% 1.4% 0.0% 1.0% 5.0% 2.1% — — 0.0% 0.0% 0.0% 1.3% 2.2% 3.2% 3.8% 4.0% 4.1% 7.0% 6.8% 6.0% 6.01%
FCF Payout Ratio — — — — — 17.3% 3.3% 1.2% 0.0% 0.0% 0.0% 1.4% 4.1% 13.1% — — — — — — —
Total Payout Ratio 3.2% 1.4% 0.0% 1.0% 5.0% 2.1% — — 0.0% 0.0% 0.0% 1.3% 2.2% 3.2% 3.8% 4.0% 4.1% 7.0% 6.8% 6.0% 6.01%
Div. Increase Streak 0 0 — 0 0 0 0 0 — — — 0 0 0 0 0 1 1 1 1 0
Chowder Number -0.43 -0.75 — -0.83 -0.50 -0.00 — 0.00 — — — 0.00 — — — 3.33 1.33 2.09 1.40 1.23 1.228
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -0.5% -0.8% -0.7% -1.4% -1.7% -1.5% -1.2% -1.0% -0.9% -0.90%
Total Shareholder Return 0.2% 0.1% 0.0% 0.1% 0.2% 0.2% 0.2% 0.1% 0.0% 0.0% 0.0% -0.4% -0.7% -0.7% -1.3% -1.6% -1.4% -0.9% -0.8% -0.7% -0.72%
DuPont Factors
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Tax Burden (NI/EBT) 0.72 0.71 0.66 0.91 1.13 -0.05 0.22 -1.53 0.48 0.63 0.67 0.75 0.75 0.74 0.75 0.74 0.74 0.75 0.74 0.78 0.781
Interest Burden (EBT/EBIT) 0.89 0.89 0.87 0.79 0.55 -1.62 17.17 0.19 0.57 0.66 0.69 0.75 0.79 0.81 0.85 0.85 0.86 0.87 0.86 0.95 0.953
EBIT Margin 0.20 0.22 0.22 0.17 0.10 0.02 -0.00 0.05 0.09 0.11 0.13 0.13 0.13 0.13 0.13 0.14 0.14 0.15 0.16 0.15 0.155
Asset Turnover 0.86 0.84 0.80 0.62 0.50 0.46 0.49 0.60 0.68 0.65 0.67 0.74 0.77 0.73 0.74 0.72 0.74 0.71 0.74 0.71 0.705
Equity Multiplier 1.87 1.91 1.91 1.90 1.90 1.91 1.91 1.87 1.87 1.97 1.97 1.92 1.92 2.03 2.03 1.86 1.86 1.86 1.86 1.76 1.764
Per Share
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
EPS (Diluted TTM) $9.33 $10.76 $9.39 $7.33 $3.03 $0.07 $-0.54 $-0.89 $1.73 $3.35 $4.26 $5.89 $6.74 $7.03 $7.79 $8.15 $8.25 $9.46 $9.89 $11.16 $11.16
Book Value/Share $48.44 $53.69 $54.26 $55.63 $55.62 $54.13 $53.52 $54.40 $54.40 $56.58 $56.58 $63.36 $63.46 $66.75 $66.42 $75.39 $72.11 $81.83 $80.48 $85.99 $83.81
Tangible Book/Share $48.25 $53.48 $54.06 $55.47 $55.46 $53.94 $53.32 $54.23 $54.23 $56.38 $56.38 $63.04 $63.15 $66.46 $66.13 $75.14 $71.87 $81.54 $80.19 $85.69 $85.69
Revenue/Share $72.08 $77.43 $74.96 $60.92 $49.25 $47.93 $50.64 $61.67 $70.05 $70.90 $72.40 $83.79 $87.37 $91.02 $91.97 $92.26 $91.81 $96.49 $98.99 $97.05 $95.94
FCF/Share $-3.79 $-5.52 $-7.32 $-5.05 $-2.86 $0.88 $4.60 $6.10 $7.53 $7.49 $7.46 $5.52 $3.64 $1.72 $-0.24 $-1.91 $-3.43 $-1.94 $-3.47 $-4.37 $1.35
OCF/Share $7.68 $9.19 $10.80 $9.21 $7.73 $7.04 $6.21 $6.90 $7.53 $7.49 $7.46 $7.06 $6.73 $6.35 $5.91 $6.33 $6.46 $9.77 $10.01 $9.20 $4.51
Cash/Share $4.77 $3.59 $3.63 $5.51 $5.51 $0.08 $0.08 $0.87 $0.87 $4.56 $4.56 $4.27 $4.27 $2.47 $2.46 $4.90 $4.69 $11.45 $11.26 $5.04 $0.00
EBITDA/Share $17.47 $20.27 $19.75 $14.08 $8.67 $4.70 $3.65 $7.02 $10.17 $11.88 $13.03 $14.30 $15.30 $15.80 $16.29 $17.12 $16.94 $18.77 $19.79 $19.38 $19.38
Debt/Share $30.04 $29.17 $29.48 $31.14 $31.14 $30.32 $29.97 $30.01 $30.01 $32.69 $32.69 $33.17 $33.22 $33.80 $33.63 $36.63 $35.03 $36.39 $35.78 $39.95 $39.95
Net Debt/Share $25.27 $25.58 $25.85 $25.63 $25.63 $30.24 $29.90 $29.14 $29.14 $28.13 $28.13 $28.90 $28.95 $31.32 $31.17 $31.72 $30.34 $24.94 $24.52 $34.91 $34.91
Academic Models
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 5.280
Altman Z-Prime snapshot only 9.408
Piotroski F-Score 6 6 8 6 6 5 3 5 6 7 8 7 6 7 7 7 7 7 6 7 7
Beneish M-Score -1.79 -2.10 -2.00 -2.24 -2.90 -2.56 -2.65 -1.48 -1.60 -2.51 -2.27 -1.41 -1.65 -1.91 -1.96 -2.38 -2.50 -2.32 -1.84 -2.12 -2.124
Ohlson O-Score snapshot only -9.067
ROIC (Greenblatt) snapshot only 14.62%
Net-Net WC snapshot only $6.72
EVA snapshot only $-79183680.54
Credit
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Credit Rating snapshot only A-
Credit Score 74.63 67.75 59.07 51.95 41.81 27.33 25.47 40.49 51.83 50.27 50.34 63.20 65.21 66.55 62.27 67.16 69.67 68.85 71.82 69.75 69.754
Credit Grade snapshot only 7
Credit Trend snapshot only 2.593
Implied Spread (bps) snapshot only 175.000
Industry Credit Rank snapshot only 48
Sector Credit Rank snapshot only 69

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms